Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist
- 1 September 1994
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 2 (9) , 897-908
- https://doi.org/10.1016/s0968-0896(00)82039-8
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet AggregationJournal of Medicinal Chemistry, 1994
- Development of GPIIb/IIIa antagonists as antithrombotic drugsTrends in Pharmacological Sciences, 1992
- Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thromboiysisCoronary Artery Disease, 1992
- Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitroJournal of Medicinal Chemistry, 1991
- Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cellsCell, 1989
- Platelet receptor recognition domain on the .gamma. chain of human fibrinogen and its synthetic peptide analoguesBiochemistry, 1989
- New Perspectives in Cell Adhesion: RGD and IntegrinsScience, 1987
- Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectinBlood, 1985
- Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the moleculeNature, 1984
- Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the .gamma. chainBiochemistry, 1984